Exelixis | EXEL - Operating Profit



Exelixis reported $215.68M in Operating Profit for its fiscal quarter ending in July of 2025.


Operating Profit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Amgen USD 2.66B 1.37B Jun/2025
AstraZeneca USD 3.51B 166M Jun/2025
Bayer EUR 13M 2.31B Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Bristol-Myers Squibb USD 3.77B 366M Jun/2025
Cytokinetics USD -111506000 44.12M Jun/2025
Eisai JPY 20.74B 21.77B Jun/2025
Eli Lilly USD 7.02B 1.61B Jun/2025
Exelixis USD 215.68M 28.82M Jul/2025
Genmab DKK 360M 172M Jun/2025
Glaxosmithkline GBP 2.44B 1.74B Jun/2025
Incyte USD 310.82M 105.66M Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
MacroGenics USD -36760000 20.17M Jun/2025
Merck USD 6.36B 494M Jun/2025
Moderna USD -907000000 143M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD 4.86B 201M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
Sanofi EUR 1.71B 851M Jun/2025
Takeda JPY 184.56B 259.5B Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Xencor USD -33172000 10.01M Jun/2025